Actively Recruiting
Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease
Led by Emory University · Updated on 2026-03-02
10
Participants Needed
1
Research Sites
75 weeks
Total Duration
On this page
Sponsors
E
Emory University
Lead Sponsor
N
National Institute on Aging (NIA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
In people with Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD), reduced capacity for locomotor adaptation is a fundamental but poorly understood mechanism that can be a sensitive biomarker of cognitive-motor impairments. It is also an important therapeutic target for exercise-based interventions to improve walking function. The overall goal of this study is to understand the effects of MCI and AD on locomotor adaptation and walking function.
CONDITIONS
Official Title
Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have a formal diagnosis of Alzheimer's Disease or Mild Cognitive Impairment confirmed by a board-certified neurologist
- Mild Cognitive Impairment must be amnestic subtype defined by AD Neuroimaging Initiative criteria
- Subjective memory concern or memory problem noted by a partner
- Abnormal memory function documented by education adjusted cutoff on delayed paragraph recall test
- Mini-Mental State Exam score between 20 and 26 (inclusive) with possible exceptions for less than 8 years education
- Clinical Dementia Rating of 0.5 with Memory Box score at least 0.5
- General functional performance sufficiently preserved
- Evidence of impaired executive function with Montreal Cognitive Assessment score between 13 and 17
- Able to walk 10 or more feet without an assistive device
- Completed at least six grades of education or has a good work history
- Not hospitalized within the last 60 days
You will not qualify if you...
- Acute medical illness requiring hospitalization
- Uncontrolled congestive heart failure
- History of stroke
- Inability to perform study procedures
- Medical or physical conditions precluding participation or walking (e.g., severe arthritis, uncontrolled hypertension or diabetes, renal failure, angina with activity)
- Use of medications that may adversely affect cognition (e.g., antipsychotics, opioids, stimulants, chemotherapy, anti-parkinsonian drugs like Levodopa, neurologic drugs for Multiple sclerosis or Parkinson's)
- Psychotic disorders
- Confounding neurologic conditions (e.g., active CNS infections, seizure disorders, head injury with loss of consciousness >30 minutes, intracranial tumors, stroke with neurological or neuropsychiatric effects)
- Substance use disorder, major depressive disorder, or generalized anxiety disorder within six months of evaluation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Emory Rehabilitation Hospital
Atlanta, Georgia, United States, 30322
Actively Recruiting
Research Team
T
Trisha Kesar, PT, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here